Navigation Links
Calando Pharmaceuticals Publishes the First Non-Human Primate Study,on Targeted, Systemic Delivery of siRNA in National Academy of,Sciences Journal

human use.

"The experimental work reported in this paper shows that CALAA-01 can safely be repeatedly administered to large animals," said Jeremy Heidel, Calando's Chief Scientific Officer. "We observed a lack of significant immunostimulation and, notably, the absence of complement activation, even at the highest dose administered. The results of this study are promising and suggest further investigation of CALAA-01 is warranted."

"These results demonstrate that our lead siRNA formulation CALAA-01is well tolerated at levels many times higher than what we would expect to be an efficacious dose in humans," said John Petrovich, Calando's Chief Executive Officer. "We are proceeding with full IND-enabling toxicology studies as the next step toward commencing what we believe will be the first Phase I clinical trial with a targeted, systemic formulation of siRNA by the end of 2007."

Established in 1914, PNAS is one of the world's most-cited multidisciplinary scientific serial publications. Coverage in PNAS includes research reports, commentaries, reviews, perspectives and colloquium papers that span the biological, physical and social sciences, as well as the actions of the Academy. PNAS is published weekly in print, and daily online in PNAS Early Edition at http://www.pnas.org.

About RNA Interference (RNAi)

RNA interference, or RNAi, is a naturally occurring mechanism within cells for selectively silencing and regulating specific genes. Since many diseases are caused by the inappropriate activity of specific genes, the ability to silence genes selectively through RNAi could provide a new way to treat a wide range of human diseases. RNAi is induced by small, double-stranded RNA molecules. One method to activate RNAi is with chemically synthesized small interfering RNAs, or siRNAs, which are double-stranded RNAs that are targeted to a specific disease-associated gene. The siRNA molecules are used by the natural RNAi machinery in cells to c
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Calando Pharmaceuticals Announces Preclinical Efficacy and Safety Data of Targeted, Systemic Delivery of siRNA at AACR Annual Meeting
2. Arrowhead Subsidiaries Insert & Calando Present Data on Cyclosert Drug Delivery System at AACR Meeting
3. Arrowhead Subsidiary Calando Pharmaceuticals Publishes Study Showing Anti-Cancer Effect with Lead RNAi Candidate
4. Calando Pharmaceuticals Publishes Study Showing Anti-Cancer Effect with Lead RNAi Candidate
5. Arrowhead Subsidiary, Calando Pharmaceuticals Publishes Study on Targeted, Systemic Delivery of siRNA
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
10. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
11. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:11/25/2008)...e recovery , , Audio and Web Video Resource...o Clinic News Blog. Please see the bottom of this ...nn., Nov. 25 A Mayo Cli...t think they,re having a stroke -- and as a result...worsens. The findings appear in the current issue ...
(Date:11/25/2008)... Nov. 25 Proteolix, Inc., a,leade...eutics that target,protein degradation pathways i... that data from two ongoing Phase 2 clinical trial...ented at the upcoming 50th Annual Meeting of the,... is the first in a new class,of specific proteaso...
(Date:11/25/2008)...nical Trial to Assess Survival of Patients Receivi...sectable Hepatocellular Carcinoma , , BELLE... Oncology, Inc. (LSO) today announced the completi...l of Light Infusion Therapy(TM) (Litx(TM)) as a tr...(HCC), also known as hepatoma or primary liver can...
(Date:11/24/2008)...RNewswire/ -- Domino,s Pizza (NYSE: DPZ ), the,...ing up to raise dough for,the kids of St. Jude Ch...,Thanks and Giving campaign. Domino,s customers w...int of purchase to benefit the children of St. Jud...hone or when ordering online at, www.dominos.com ...
Breaking Medicine Technology:Do You Know You're Having a Stroke? 2Do You Know You're Having a Stroke? 3Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 2Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 3Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 2Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 3Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 4Domino's Pizza Pledges Support to the Fifth Annual St. Jude Children's Research Hospital(R) Thanks and Giving(R) Campaign 2Domino's Pizza Pledges Support to the Fifth Annual St. Jude Children's Research Hospital(R) Thanks and Giving(R) Campaign 3July 2008 Mayo Clinic Health Letter Highlights Bone Health Causes of Swelling and Slimmed Down Desserts 23953 1July 2008 Mayo Clinic Health Letter Highlights Bone Health Causes of Swelling and Slimmed Down Desserts 23953 2July 2008 Mayo Clinic Health Letter Highlights Bone Health Causes of Swelling and Slimmed Down Desserts 23953 3July 2008 Mayo Clinic Health Letter Highlights Bone Health Causes of Swelling and Slimmed Down Desserts 23953 4Spherix Expands Phase 3 Naturlose Diabetes Trial Outside of the U S 2626 1Spherix Expands Phase 3 Naturlose Diabetes Trial Outside of the U S 2626 2Government Ill Equipped to Prevent Medicaid Fraud Says False Claims Act Expert 23946 1Government Ill Equipped to Prevent Medicaid Fraud Says False Claims Act Expert 23946 2Two New Jersey Hormone Therapy Lawsuits Dismissed 6534 1
...O VIEJO, Calif.--(BUSINESS WIRE)--Jun 8, 2007 - AV... the presentation of,Phase III data, including eff... outcomes in patients with diabetic peripheral,neu...al drug,Zenvia(TM) (dextromethorphan/quinidine (DM...ist. The data were accepted as,late-breakers, and...
...RIDGE, Mass.--(BUSINESS WIRE)--Jun 8, 2007 - Arche...overing and developing,aptamers, announced the suc... aptamer therapeutic, ARC1779. ARC1779 is designed... aggregation of,platelets by inhibiting the bindin...tor on platelets. Activated vWF is scientifically,...
Other Medicine Technology:AVANIR Pharmaceuticals Presents Zenvia Phase III Data in Diabetic,Peripheral Neuropathic Pain at International Congress on,Neuropathic Pain 2AVANIR Pharmaceuticals Presents Zenvia Phase III Data in Diabetic,Peripheral Neuropathic Pain at International Congress on,Neuropathic Pain 3AVANIR Pharmaceuticals Presents Zenvia Phase III Data in Diabetic,Peripheral Neuropathic Pain at International Congress on,Neuropathic Pain 4AVANIR Pharmaceuticals Presents Zenvia Phase III Data in Diabetic,Peripheral Neuropathic Pain at International Congress on,Neuropathic Pain 5AVANIR Pharmaceuticals Presents Zenvia Phase III Data in Diabetic,Peripheral Neuropathic Pain at International Congress on,Neuropathic Pain 6AVANIR Pharmaceuticals Presents Zenvia Phase III Data in Diabetic,Peripheral Neuropathic Pain at International Congress on,Neuropathic Pain 7Archemix Announces Completion of Phase 1 Trial of ARC1779 2Archemix Announces Completion of Phase 1 Trial of ARC1779 3
(Date:12/2/2008)...Resilient, Cost and Energy Efficient Information I... EMC Corporation (NYSE: EMC ), th...ions, today announced that the Daughters of Charit...ospitals spanning the California coast, has consol...s continuity functions to deliver new online clini...
(Date:12/2/2008)...valuate Efficacy of Commercially Available Hypomet...Dec. 2 Eisai Corporation of North ...the first clinical trial evaluating the activity o...o Vidaza(R) (azacitidine) in adult patients with i...splastic syndromes (MDS), a potentially life-threa...
(Date:12/2/2008)...arotz Dental is now one of only two dental,practi...ew Attachment,Procedure). This is the only laser...approved for new attachment of gum and bone tissue...sue, without removing healthy tissue, maintains,t...in and discomfort to the,patient, closes the peri...
(Date:12/2/2008)...Call/ -- Global Med Technologies(R), Inc.,("Globa...), an international,e-Health, medical information...opean subsidiary, Inlog S.A., has licensed its Edg...rveur" in France, to 21 Assistance Publique -,Hop...3,000 patient beds. For,Global Med, this project ...
Breaking Medicine News(10 mins):Health News:Daughters of Charity Health System Improves IT Efficiency and Accelerates Time-to-Treatment with EMC 2Health News:Daughters of Charity Health System Improves IT Efficiency and Accelerates Time-to-Treatment with EMC 3Health News:Daughters of Charity Health System Improves IT Efficiency and Accelerates Time-to-Treatment with EMC 4Health News:Eisai Will Initiate First Head-to-Head Study Comparing Dacogen(R) (decitabine for injection) and Vidaza(R) (azacitidine) in Patients with Myelodysplastic Syndromes 2Health News:Eisai Will Initiate First Head-to-Head Study Comparing Dacogen(R) (decitabine for injection) and Vidaza(R) (azacitidine) in Patients with Myelodysplastic Syndromes 3Health News:Barotz Dental Now Offering Laser Gum Therapy 2Health News:Global Med Technologies(R)' European Subsidiary to Provide Strategic Blood Transfusion Software for 21 Paris Hospitals 2Health News:Global Med Technologies(R)' European Subsidiary to Provide Strategic Blood Transfusion Software for 21 Paris Hospitals 3Health News:Global Med Technologies(R)' European Subsidiary to Provide Strategic Blood Transfusion Software for 21 Paris Hospitals 4
...armaceuticals Inc (RPI) has received a tentative a...sinopril is recommended for hypertension, either a...anti-hypertenive agents. It is also used as adjunc...t failure and patients who do not respond to diure...
...s of drugs based on a widely used anticancer drug,...fects in the laboratory and in mice, according to ...eresting for the treatment of these tumors. // Pr...were extremely active in blocking the same cell ta...
...ro, Cipro. That's been the mantra of the media as ...ds who weren't -- clamor for the potent antibiotic...eaper and widely available medications can be used... penicillin. Although alternatives exist, Cipro is...
...ental anti-cancer drug has shown effectiveness in ...o a new report. Researchers say the drug probably ...seful for treating other types of cancer. Dr. Anto...esda, Maryland, and colleagues tested the drug, de...
Other Medicine News:
Standard reading test. "Clearing weather..."
Directional `E' and `C' test.
...These Low Contrast Flip charts contain 5 pages of ...ach page. Optotype size is 9.5M. Contrast levels a... can be used at several different distances. These...a different set of symbols to guard against memor...
...The PowerLab/4SP is a high-performance data acquis... applications including human and animal physiolog..., biochemistry, and biomedical engineering. The un...fast speeds (up to 200 000 samples per second cont...
Medicine Products: